Loading clinical trials...
Loading clinical trials...
A Phase IIb Randomized, Double Blind, Comparative Study to Assess the Efficacy, Safety, Tolerability and Inhibition of Ovulation of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days
Conditions
Interventions
Ulipristal Acetate
Locations
10
United States
California Family Health Council
Los Angeles, California, United States
University of California, San Francisco
San Francisco, California, United States
University of Colorado - Denver Anschutz Medical Campus
Aurora, Colorado, United States
University of Chicago
Chicago, Illinois, United States
NYU School of Medicine
New York, New York, United States
Columbia University Medical Center
New York, New York, United States
Start Date
March 1, 2014
Primary Completion Date
August 1, 2015
Completion Date
November 1, 2015
Last Updated
February 22, 2016
Lead Sponsor
Premier Research
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions